Standout Papers

Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 <sup>+</sup> and CD4 <s... 2015 2026 2018 2022 734
  1. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells (2016)
    Cameron J. Turtle, Laïla‐Aïcha Hanafi et al. Science Translational Medicine
  2. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo (2015)
    Daniel Sommermeyer, Michael Hudecek et al. Leukemia
  3. The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells (2019)
    Katrin Mestermann, Theodoros Giavridis et al. Science Translational Medicine

Immediate Impact

9 by Nobel laureates 33 from Science/Nature 165 standout
Sub-graph 1 of 11

Citing Papers

Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies
2025 Standout
CAR-T cell manufacturing: Major process parameters and next-generation strategies
2024 Standout
163 intermediate papers

Works of Michael Hudecek being referenced

CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma
2021
Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors
2016
and 31 more

Author Peers

Author Last Decade Papers Cites
Michael Hudecek 5199 1972 2304 108 6.2k
Rimas J. Orentas 6378 2878 2132 118 8.0k
Nirali N. Shah 5721 1919 1739 208 7.1k
Shannon L. Maude 7458 2496 2096 107 8.9k
Martin Pulé 7016 3233 2934 147 9.1k
Carlos A. Ramos 4218 1954 2070 104 6.0k
Zhaohui Zheng 5497 2056 1733 31 6.3k
Nabil Ahmed 4032 1733 1285 84 5.6k
Claudia Rössig 4254 2352 1354 155 5.6k
Saar Gill 4237 2959 1904 173 6.6k
Angela Shen 5047 1746 1777 36 6.1k

All Works

Loading papers...

Rankless by CCL
2026